Arca biopharma reports topline results for aspen-covid-19 phase 2b clinical trial

Westminster, colo., march 31, 2022 (globe newswire) -- arca biopharma, inc. (nasdaq: abio), today announced results for aspen-covid-19, a 160 patient phase 2b clinical trial evaluating rnapc2, a highly potent and specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with covid-19. in the clinical trial, both doses of rnapc2 demonstrated a treatment benefit for patients, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in d-dimer level from baseline to day 8 compared to standard of care heparin.
ABIO Ratings Summary
ABIO Quant Ranking